MRC1 and metastatic neoplasm: With this strategy, >70% of missense mutations involving MMR genes were filtered, and the percentage of MMR-d tumors (2.59% in primary tumors and 4.26% in metastatic tumors) is consistent with previous studies (3–5%) [11,12,14].